Zacks Research Analysts Lower Earnings Estimates for HealthEquity, Inc. (NASDAQ:HQY)

HealthEquity, Inc. (NASDAQ:HQY) – Zacks Research reduced their Q3 2025 earnings estimates for shares of HealthEquity in a note issued to investors on Tuesday, September 24th. Zacks Research analyst R. Department now forecasts that the company will earn $0.51 per share for the quarter, down from their prior forecast of $0.54. The consensus estimate for HealthEquity’s current full-year earnings is $2.25 per share. Zacks Research also issued estimates for HealthEquity’s Q1 2026 earnings at $0.69 EPS.

HQY has been the topic of a number of other research reports. Royal Bank of Canada restated an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a report on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Barrington Research reiterated an “outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a research note on Friday, September 20th. Robert W. Baird increased their price objective on shares of HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a research note on Tuesday, June 4th. Finally, KeyCorp raised their price target on shares of HealthEquity from $95.00 to $100.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 5th. One investment analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $103.83.

HealthEquity Price Performance

HQY stock opened at $79.93 on Thursday. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10. HealthEquity has a 1 year low of $61.81 and a 1 year high of $88.26. The stock has a market capitalization of $6.95 billion, a PE ratio of 86.88, a price-to-earnings-growth ratio of 1.25 and a beta of 0.52. The company’s 50-day moving average is $76.29 and its 200-day moving average is $79.26.

Hedge Funds Weigh In On HealthEquity

A number of large investors have recently added to or reduced their stakes in the business. GM Advisory Group LLC increased its position in shares of HealthEquity by 300.8% in the fourth quarter. GM Advisory Group LLC now owns 120,355 shares of the company’s stock valued at $7,980,000 after acquiring an additional 90,329 shares during the period. Forest Hill Capital LLC purchased a new position in shares of HealthEquity in the fourth quarter valued at about $2,021,000. Norges Bank purchased a new position in shares of HealthEquity in the fourth quarter valued at about $43,482,000. Vanguard Group Inc. increased its position in shares of HealthEquity by 1.7% in the first quarter. Vanguard Group Inc. now owns 8,768,632 shares of the company’s stock valued at $715,783,000 after acquiring an additional 149,133 shares during the period. Finally, Diversify Advisory Services LLC purchased a new position in shares of HealthEquity in the first quarter valued at about $7,828,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

Insider Buying and Selling

In related news, Vice Chairman Stephen Neeleman sold 35,000 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $79.86, for a total value of $2,795,100.00. Following the completion of the transaction, the insider now directly owns 89,769 shares of the company’s stock, valued at approximately $7,168,952.34. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, Director Frank Corvino sold 7,705 shares of the firm’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $81.89, for a total transaction of $630,962.45. Following the sale, the director now owns 6,070 shares in the company, valued at approximately $497,072.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Vice Chairman Stephen Neeleman sold 35,000 shares of the firm’s stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $79.86, for a total transaction of $2,795,100.00. Following the sale, the insider now owns 89,769 shares in the company, valued at approximately $7,168,952.34. The disclosure for this sale can be found here. 2.20% of the stock is owned by insiders.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.